The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

    Chemcon Specialty Chemicals IPO subscribed 149 times; grey market premium rises to 88%

    Synopsis

    The Vadodara-based company plans to raise Rs 318 crore, out of which it already raised Rs 95.40 crore through allotment of 28.06 lakh shares to anchor investors at Rs 340 per share last week.

    iStock
    Analysts said that the issue is demanding an inexpensive valuation of 25.5 times FY20 earnings per share and that the company could gain from a shift in demand from China. But high client concentration, criminal proceeding against a promoter and limited portfolio are risks to the company.
    NEW DELHI: The initial public offering (IPO) of Chemcon Speciality Chemicals was subscribed 149.14 times on Day 3 of the bidding process. The issue had received applications for 97,64,26,440 shares against 65,59,173 shares on offer.

    “Such oversubscription was in line with our expectation, as we believe a lot is left on the table for the investors by comparing its valuation with other speciality chemical companies. We are positive on the future outlook for the industry as well as the company. So, in our IPO note we have recommended a “Subscribe” rating to the issue for long term as well as for listing gains,” said Keshav Lahoti, Associate Equity Analyst, Angel Broking.

    “Due to its position as a leading manufacturer of its products globally, it is getting strong traction among investors. But, product concentration and client concentration risk cannot be ruled out. Although Company clients are sticky in nature, they have long-standing relationships. Aurobindo Pharma has been its client for more than 20 years,” he added.

    The Vadodara-based company plans to raise Rs 318 crore, out of which it already raised Rs 95.40 crore through allotment of 28.06 lakh shares to anchor investors at Rs 340 per share last week.

    The company is offering a fresh issue of equity shares, aggregating up to Rs 165 crore and offer for sale of up to 45,00,000 equity shares, to be sold in the price range of Rs 338-Rs 340.

    In the grey market, the shares of the company were trading with a premium of Rs 300 per share, that is, 88 per cent more than the price band set for the initial public offering.

    Analysts said that the issue is demanding an inexpensive valuation of 25.5 times FY20 earnings per share and that the company could gain from a shift in demand from China. But high client concentration, criminal proceeding against a promoter and limited portfolio are risks to the company.

    Most brokers had ‘subscribe’ ratings on the stock. Angel Broking said the company's return ratios and margins are better than most of its peers, adding that the company is undervalued compared to its peers and "a lot of value is left in the table".

    "As we are positive on the future outlook for the industry as well as the company, we would recommend to “Subscribe” issue for long term as well as for listing gains," it said.
    (What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Also Read

    2 Comments on this Story

    Binu Pillai32 days ago
    Covid cases are increasing, Vitamin-D is the best immunity booster. Look at Fermenta Biotech pharma which is the largest producer of Vitamin-D . It has posted fantastic results ( EBIDTA 34%, PAT 27% ).. Share appreciation mainly thru BONUS issues ... Read their investor presentation and understand the worth of the company. Invest for long term.
    Dinesh Agarwal33 days ago
    The subscription status shows just like Happiest Minds and Route Mobiles. Let us hope for a good listing in market.
    The Economic Times